Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
- Conditions
- SepsisHematologic NeoplasmsHematopoietic Stem Cell TransplantationInfection
- Interventions
- First Posted Date
- 2003-08-27
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT00067730
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States
Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-07-29
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 92
- Registration Number
- NCT00065533
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- First Posted Date
- 2003-07-22
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00065312
- Locations
- 🇺🇸
For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559), Spokane, Washington, United States
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2003-07-01
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 73
- Registration Number
- NCT00063570
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., San Juan, Puerto Rico
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Biological: Cetuximab
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT00063388
- Locations
- 🇺🇸
ImClone Investigational Site, Saint Louis, Missouri, United States
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Conditions
- Ovarian CancerPeritoneal NeoplasmsFallopian Tube Neoplasms
- Interventions
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT00063401
- Locations
- 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: human insulin inhalation powder (HIIP)
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 119
- Registration Number
- NCT00063128
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1302
- Registration Number
- NCT00063141
- Locations
- 🇬🇧
ImClone Investigational Site, Sutton, Surrey, United Kingdom
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
- Conditions
- DepressionCognition
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 311
- Registration Number
- NCT00062673
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleton, Wisconsin, United States
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 102
- Registration Number
- NCT00061815
- Locations
- 🇺🇸
ImClone Investigational Site, Richmond, Virginia, United States